Concerns regarding the association of hormone therapy used to treat prostate cancer with cardiovascular disease in some older men may lead doctors to forgo hormone treatment solely on the basis of age. But a new study shows that men over age 70 with high-risk prostate cancer lived longer and experienced increases in PSA less frequently when treated with long-term androgen deprivation therapy.

Using one of the largest databases of prostate cancer outcomes in the United States, Fox Chase Cancer Center researchers have developed a prediction tool that uses a patient’s clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.

In an advance toward a long-sought new male contraceptive, researchers in China have identified key proteins in men that suppress production of sperm and could become new targets for a future male birth control pill.

Scientists from China have isolated CD44+CD24+ subpopulation cells which have properties of tumor stem cells. Because cancer stem cells are thought to be responsible for tumor initiation, it may be a very promising target for new drug developments.